Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 2
1967 1
1978 1
1980 1
1981 1
1982 2
1983 1
1984 2
1985 1
1986 1
1987 2
1988 3
1989 4
1990 1
1991 5
1993 1
1994 5
1995 5
1996 5
1997 1
1998 5
1999 5
2000 1
2001 7
2002 2
2003 4
2004 3
2005 9
2006 5
2007 4
2008 2
2009 4
2010 5
2011 3
2012 8
2013 8
2014 12
2015 11
2016 15
2017 7
2018 4
2019 12
2020 7
2021 9
2022 15
2023 10
2024 18
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S, Haindl S, Kasbohm S, Kainz A, Eskandary F, Doberer K, Patel UD, Dudani JS, Regele H, Kozakowski N, Kläger J, Boxhammer R, Amann K, Puchhammer-Stöckl E, Vietzen H, Beck J, Schütz E, Akifova A, Firbas C, Gilbert HN, Osmanodja B, Halleck F, Jilma B, Budde K, Böhmig GA. Mayer KA, et al. Among authors: diebold m. N Engl J Med. 2024 Jul 11;391(2):122-132. doi: 10.1056/NEJMoa2400763. Epub 2024 May 25. N Engl J Med. 2024. PMID: 38804514 Clinical Trial.
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.
Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron KS, Benseler S, Berard R, Broderick L, Dedeoglu F, Diebold M, Durrant KL, Ferguson P, Foell D, Hausmann J, Jones OY, Kastner DL, Lachmann HJ, Laxer RM, Rivera D, Ruperto N, Simon A, Twilt M, Frenkel J, Hoffman H, de Jesus AA, Kuemmerle-Deschner JB, Ozen S, Gattorno M, Goldbach-Mansky R, Demirkaya E. Romano M, et al. Among authors: diebold m. Ann Rheum Dis. 2022 Jul;81(7):907-921. doi: 10.1136/annrheumdis-2021-221801. Epub 2022 May 27. Ann Rheum Dis. 2022. PMID: 35623638 Free article.
ADAR1 averts fatal type I interferon induction by ZBP1.
Jiao H, Wachsmuth L, Wolf S, Lohmann J, Nagata M, Kaya GG, Oikonomou N, Kondylis V, Rogg M, Diebold M, Tröder SE, Zevnik B, Prinz M, Schell C, Young GR, Kassiotis G, Pasparakis M. Jiao H, et al. Among authors: diebold m. Nature. 2022 Jul;607(7920):776-783. doi: 10.1038/s41586-022-04878-9. Epub 2022 Jul 20. Nature. 2022. PMID: 35859176 Free PMC article.
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.
Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron K, Benseler S, Berard RA, Broderick L, Dedeoglu F, Diebold M, Durrant K, Ferguson P, Foell D, Hausmann JS, Jones OY, Kastner D, Lachmann HJ, Laxer RM, Rivera D, Ruperto N, Simon A, Twilt M, Frenkel J, Hoffman HM, de Jesus AA, Kuemmerle-Deschner JB, Ozen S, Gattorno M, Goldbach-Mansky R, Demirkaya E. Romano M, et al. Among authors: diebold m. Arthritis Rheumatol. 2022 Jul;74(7):1102-1121. doi: 10.1002/art.42139. Epub 2022 May 27. Arthritis Rheumatol. 2022. PMID: 35621220 Free PMC article.
Development and validation of the Nancy histological index for UC.
Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, Danese S, Reinisch W, Schreiber S, Travis S, Peyrin-Biroulet L. Marchal-Bressenot A, et al. Among authors: diebold md. Gut. 2017 Jan;66(1):43-49. doi: 10.1136/gutjnl-2015-310187. Epub 2015 Oct 13. Gut. 2017. PMID: 26464414
The astrocyte-produced growth factor HB-EGF limits autoimmune CNS pathology.
Linnerbauer M, Lößlein L, Vandrey O, Peter A, Han Y, Tsaktanis T, Wogram E, Needhamsen M, Kular L, Nagel L, Zissler J, Andert M, Meszaros L, Hanspach J, Zuber F, Naumann UJ, Diebold M, Wheeler MA, Beyer T, Nirschl L, Cirac A, Laun FB, Günther C, Winkler J, Bäuerle T, Jagodic M, Hemmer B, Prinz M, Quintana FJ, Rothhammer V. Linnerbauer M, et al. Among authors: diebold m. Nat Immunol. 2024 Mar;25(3):432-447. doi: 10.1038/s41590-024-01756-6. Epub 2024 Feb 26. Nat Immunol. 2024. PMID: 38409259 Free PMC article.
Chronic Rejection After Kidney Transplantation.
Diebold M, Mayer KA, Hidalgo L, Kozakowski N, Budde K, Böhmig GA. Diebold M, et al. Transplantation. 2025 Apr 1;109(4):610-621. doi: 10.1097/TP.0000000000005187. Epub 2024 Aug 28. Transplantation. 2025. PMID: 39192468 Free PMC article. Review.
Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5.
Callegari I, Oechtering J, Schneider M, Perriot S, Mathias A, Voortman MM, Cagol A, Lanner U, Diebold M, Holdermann S, Kreiner V, Becher B, Granziera C, Junker A, Du Pasquier R, Khalil M, Kuhle J, Kappos L, Sanderson NSR, Derfuss T. Callegari I, et al. Among authors: diebold m. Brain. 2024 Mar 1;147(3):839-848. doi: 10.1093/brain/awad424. Brain. 2024. PMID: 38123517 Free PMC article.
[Radiocontrast agents: wrongfully accused?].
Diebold M, Kistler AD. Diebold M, et al. Ther Umsch. 2018;75(6):359-364. doi: 10.1024/0040-5930/a001009. Ther Umsch. 2018. PMID: 30880616 Review. German.
232 results